Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. REG1 is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a range of acute coronary syndromes (ACS), undergoing a percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. REG1 consists of pegnivacogin, an anticoagulant aptamer, and its specific active control agent, anivamersen. Pegnivacogin achieves its maximal anticoagulant effect within five minutes of injection.